Posted by Michael Wonder on 26 Sep 2023
NICE draft guidance recognises potential of new targeted treatment for type of advanced breast cancer
26 September 2023 - NICE has today published draft guidance for public consultation that does not recommend trastuzumab deruxtecan for treating advanced HER2 low breast cancer in adults.
NICE’s independent appraisal committee has asked Daiichi Sankyo for more information ahead of its next meeting.
